文献速递淋巴瘤

弥漫性大B细胞淋巴瘤诊断后两年内不良预后患者的遗传与转录组分析

Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis.
PubMed 文献 · Leukemia · 2023-12-29

该研究整合7个独立队列中2805例接受R-CHOP一线治疗的弥漫性大B细胞淋巴瘤(DLBCL)患者的临床、遗传与转录组数据,其中887例在两年内出现难治/复发(不良预后),1918例在两年时仍维持缓解(良好预后)。分析发现不良预后患者诊断肿瘤样本中TP53、MYD88、SPEN、MYC四个基因优先突变,并揭示与细胞黏附/迁移、T细胞活化/调控、PI3K及NF-κB信号通路相关的独特表达模式。研究开发并验证了一个24基因表达评分作为独立预后预测因子,并构建了在线预后预测工具。

要点

  • 不良预后患者诊断样本中TP53、MYD88、SPEN、MYC四个基因优先突变。
  • 不良预后相关表达模式涉及细胞黏附/迁移、T细胞活化/调控、PI3K及NF-κB信号通路。
  • 24基因表达评分可作为独立预后预测因子,并与现有遗传或细胞起源分型整合进一步分层高危患者。

核心结论

  • 在2805例接受R-CHOP治疗的DLBCL患者中,识别出与两年内难治/复发相关的四个优先突变基因及独特转录组模式,并开发验证了24基因表达评分作为独立预后预测因子。
  • 基于上述发现开发了在线分析工具(https://lymphprog.serve.scilifelab.se/app/lymphprog),可用于DLBCL患者的预后预测。

研究设计与样本

  • 整合来自7个独立队列的2805例接受R-CHOP治疗的DLBCL患者的临床、遗传与转录组数据。
  • 其中887例在两年内出现难治/复发疾病(不良预后),1918例在两年时仍维持缓解(良好预后)。

主要发现

  • 不良预后患者未治疗(诊断时)肿瘤样本中TP53、MYD88、SPEN、MYC四个基因优先突变。
  • 转录组分析揭示与不良预后相关的独特基因表达模式,涉及细胞黏附/迁移、T细胞活化/调控、PI3K及NF-κB信号通路。
  • 开发并验证了24基因表达评分作为治疗结局的独立预后预测因子。
  • 该评分与现有遗传或细胞起源分型整合时,可进一步分层高危患者,包括这些模型中的未分类病例。

关键数值与推荐

  • 24基因表达评分作为独立预后预测因子(原文未报告具体效应量或阈值)。

临床怎么用

  • 基于研究结果开发了在线分析工具(https://lymphprog.serve.scilifelab.se/app/lymphprog),可用于DLBCL患者的预后预测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite the improvements in clinical outcomes for DLBCL, a significant proportion of patients still face challenges with refractory/relapsed (R/R) disease after receiving first-line R-CHOP treatment. To further elucidate the underlying mechanism of R/R disease and to develop methods for identifying patients at risk of early disease progression, we integrated clinical, genetic and transcriptomic data derived from 2805 R-CHOP-treated patients from seven independent cohorts. Among these, 887 patients exhibited R/R disease within two years (poor outcome), and 1918 patients remained in remission at two years (good outcome). Our analysis identified four preferentially mutated genes (TP53, MYD88, SPEN, MYC) in the untreated (diagnostic) tumor samples from patients with poor outcomes. Furthermore, transcriptomic analysis revealed a distinct gene expression pattern linked to poor outcomes, affecting pathways involved in cell adhesion/migration, T-cell activation/regulation, PI3K, and NF-κB signaling. Moreover, we developed and validated a 24-gene expression score as an independent prognostic predictor for treatment outcomes. This score also demonstrated efficacy in further stratifying high-risk patients when integrated with existing genetic or cell-of-origin subtypes, including the unclassified cases in these models. Finally, based on these findings, we developed an online analysis tool ( https://lymphprog.serve.scilifelab.se/app/lymphprog ) that can be used for prognostic prediction for DLBCL patients.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Ren W, Wan H, Own SA, et al. Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis. Leukemia. 2023. PMID: 38158444. doi:10.1038/s41375-023-02120-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。